Updated Jan 13, 2021 · 10:55 pm Congress MP Manish Tewari. | PIB
Congress MP Manish Tewari on Wednesday raised more questions on the efficacy of the coronavirus vaccine developed by Bharat Biotech, a day after the Centre indicated that states and beneficiaries will not have an option to choose between the two approved vaccines. Experts and Congress leaders have questioned the government’s decision to clear Bharat Biotech’s vaccine, Covaxin, without the pharmaceutical company completing its phase-3 human trials.
“Till yesterday NDA/BJP [National Democratic Alliance/Bharatiya Janata Party] claimed Covaxin has been cleared for emergency use,” Tewari tweeted. “Today by not allowing [the] recipient to pick [a] vaccine of his choice is NDA/BJP making Guinea pigs out of Indians? Is roll out THE REAL Phase-3 Trial of Covaxin?”
Covid vaccine drive accelerates, doses reach far corners of India
India
Updated: Wednesday, January 13, 2021, 22:29 [IST]
New Delhi, Jan 13: The full initial procurement of 1.65 crore doses of COVID-19 vaccines has been allocated to all states and UTs in proportion to their healthcare workers database, the Health Ministry said on Wednesday.
Representational Image
As the country is set to begin a massive anti-coronavirus inoculation drive from January 16, the ministry said each vaccination session will cater to a maximum of 100 beneficiaries per day and it has advised states not to organise unreasonable numbers of vaccination per site per day . States have been advised to organise vaccination sessions taking into account 10 percent reserve/wastage doses and an average of 100 vaccinations per session each day.
New Delhi [India], January 12 (ANI) The Union Health Ministry on Tuesday said the active COVID-19 cases in the country are declining steadily and the current active cases are less than 2.2 lakhs.
The Union Health Ministry on Tuesday said the active COVID-19 cases in the country are declining steadily and the current active cases are less than 2.2 lakhs.